When was LUCA Science founded?

LUCA Science was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is LUCA Science located?

LUCA Science is headquartered in Chuo City, Japan.

How many employees does LUCA Science have?

As of Apr 30, 2026, the latest employee count at LUCA Science is 9.

Is LUCA Science a funded company?

LUCA Science is a funded company, having raised a total of $40.1M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 01, 2020.

When was the latest funding round of LUCA Science?

LUCA Science's latest funding was a $***** Series B round on Jun 06, 2022, with participation from 10 investors.

Where does LUCA Science rank among its competitors?

LUCA Science ranks 111th amongst 1406 active competitors, of which 164 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Orca Bio, which secured $250M in Jan, 2026.

Who are the top competitors of LUCA Science?

LUCA Science's top competitors include WuXi AppTec, Tenaya Therapeutics and ANI Pharmaceuticals. Among them, Orca Bio secured the most recent funding round in January, 2026.

LUCA Science - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of functional mitochondrial therapeutic agents by using drug delivery and formulation technology. It has developed a novel method to isolate proprietary functional mitochondria that are engineered for delivery to disease-targeted areas to treat damaged tissues and organs. By using drug delivery and formulation technology mitochondria can then be stored and delivered as a biopharmaceutical agent. It provides solutions for multiple therapeutic areas such as immunology, respiratory, CNS, obstetric, and many more.

Key Metrics

Founded Year

2018

Location

Chuo City, Japan

Stage

Series B

Total Funding

$40.1M in 2 rounds

Latest Funding Round

Series B, Jun 06, 2022, $*****

Investors

Daiwa Corporate Investment & 13 more

Ranked

111^th among 1406 active competitors

Employee Count

9 as on Apr 30, 2026

Similar Companies

Tenaya Therapeutics & 435 more

View LUCA Science's full profile

LUCA Science has raised a total funding of $40.1M over 2 rounds. Its first funding round was on Sep 01, 2020. Its latest funding round was a Series B round on Jun 06, 2022 for $*****. 10 investors participated in its latest round. LUCA Science has 14 institutional investors.

Here is the list of recent funding rounds of LUCA Science:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 06, 2022	8929222	Series B	4149855	1272853	9058637	1815011
Sep 01, 2020	1347159	Series A	9428471	9115266	Axil Capital	Remiges Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of LUCA Science's funding rounds and investors

The founders of LUCA Science is Masashi Suganuma. Rick Tsai is the CEO of LUCA Science.

Here are the details of LUCA Science's key team members:

Masashi Suganuma: Founder of LUCA Science.
Rick Tsai: CEO of LUCA Science.
Contact Info: 2 email addresses

View details of LUCA Science's Founder profiles and Board Members

LUCA Science's employee count trend

LUCA Science has 9 employees as of Apr 26. Here is LUCA Science's employee count trend over the years:

Uncover LUCA Science's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LUCA Science include WuXi AppTec, Tenaya Therapeutics and ANI Pharmaceuticals. Here is the list of Top 10 competitors of LUCA Science, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	79/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	Fidelity Investments, RA Capital Management ... & 7 others	70/100
3rd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	JPMorgan Chase, Ampersand Capital & 4 others	64/100
4th	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	ACE & Company, JLL Partners & 2 others	63/100
5th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	63/100
6th	Tune Therapeutics 2009, Seattle (United States), Series B	Developer of cell and gene therapy by using the epigenomic platform	$222M	New Enterprise Associates, Emerson Collective ... & 8 others	63/100
7th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Yuexiu Group & 16 others	63/100
8th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	63/100
9th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, Qualium Investissement ... & 2 others	62/100
10th	LIfT Biosciences 2016, London (United Kingdom), Series A	Developer of neutrophil-based cell therapies for solid tumors	$20.1M	Kizoo, Downing & 13 others	61/100
111th	LUCA Science 2018, Chuo City (Japan), Series B	Developer of functional mitochondrial therapeutic agents by using drug delivery and formulation technology	$40.1M	4Bio Capital, Nippon Venture Capital & 12 others	41/100